Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Atlanta, GA
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Chicago, IL
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Boston, MA
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Study Site
mi
from
Minneapolis, MN
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Study Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Cleveland, OH
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Nashville, TN
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Sydney,
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Sydney,
Click here to add this to my saved trials
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Status: Enrolling
Updated:  1/26/2018
The Christ Hospital
mi
from
Cincinnati, OH
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Status: Enrolling
Updated: 1/26/2018
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Status: Enrolling
Updated:  1/29/2018
Walter Reed Army Institute for Research
mi
from
Silver Spring, MD
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1)
Status: Enrolling
Updated: 1/29/2018
Walter Reed Army Institute for Research
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods
Improved Adherence to C. Difficile Isolation Protocols Though Improved Inter-disciplinary Educational Methods
Status: Enrolling
Updated:  1/29/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods
Improved Adherence to C. Difficile Isolation Protocols Though Improved Inter-disciplinary Educational Methods
Status: Enrolling
Updated: 1/29/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Spinal Cord Stimulation to Restore Cough
Spinal Cord Stimulation to Restore Cough
Status: Enrolling
Updated:  1/30/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Spinal Cord Stimulation to Restore Cough
Spinal Cord Stimulation to Restore Cough
Status: Enrolling
Updated: 1/30/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sub-study to Spinal Cord Stimulation to Restore Cough
Evaluation of Wire Electrodes to Activate the Expiratory Muscles to Restore Cough
Status: Enrolling
Updated:  1/30/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Sub-study to Spinal Cord Stimulation to Restore Cough
Evaluation of Wire Electrodes to Activate the Expiratory Muscles to Restore Cough
Status: Enrolling
Updated: 1/30/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia
Status: Enrolling
Updated:  1/30/2018
Sharp Grossmont Hospital
mi
from
La Mesa, CA
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia
Status: Enrolling
Updated: 1/30/2018
Sharp Grossmont Hospital
mi
from
La Mesa, CA
Click here to add this to my saved trials
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia
Status: Enrolling
Updated:  1/30/2018
Sharp Memorial Hospital
mi
from
San Diego, CA
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia
Status: Enrolling
Updated: 1/30/2018
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow Cytoreduction With Busulfan
Status: Enrolling
Updated:  2/1/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow Cytoreduction With Busulfan
Status: Enrolling
Updated: 2/1/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  2/1/2018
GSK Investigational Site
mi
from
Wichita, KA
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 2/1/2018
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  2/1/2018
GSK Investigational Site
mi
from
Columbia, MD
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 2/1/2018
GSK Investigational Site
mi
from
Columbia, MD
Click here to add this to my saved trials
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  2/1/2018
GSK Investigational Site
mi
from
Golden, CO
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 2/1/2018
GSK Investigational Site
mi
from
Golden, CO
Click here to add this to my saved trials
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated:  2/1/2018
GSK Investigational Site
mi
from
Coquitlam,
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Status: Enrolling
Updated: 2/1/2018
GSK Investigational Site
mi
from
Coquitlam,
Click here to add this to my saved trials
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
Status: Enrolling
Updated:  2/2/2018
Ucsf Aids Ctu
mi
from
San Francisco, CA
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
Status: Enrolling
Updated: 2/2/2018
Ucsf Aids Ctu
mi
from
San Francisco, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Albany, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Albany, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Martinez, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Martinez, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Applewood, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Applewood, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Aurora, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Brighton, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Brighton, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Castle Rock, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Castle Rock, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Denver, CO
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Hartford, CT
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Adamsville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Adamsville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Auburn, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Auburn, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Canton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Canton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Carrollton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Carrollton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Cartersville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Cartersville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Conyers, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Conyers, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Covington, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Covington, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Cumming, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Cumming, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Dallas, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Dallas, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Decatur, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Douglasville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Douglasville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Fayetteville, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Fayetteville, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Good Hope, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Good Hope, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Griffin, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Griffin, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Hampton, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Hampton, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Jasper, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Jasper, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Jonesboro, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Jonesboro, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Marietta, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Newnan, GA
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials